ABCC10-Mediated Oxaliplatin Resistance in Colorectal Cancer Was Alleviated by Intense Endoplasmic Reticulum Stress (ERS) / IRE1α

Abstract Background: Oxaliplatin resistance is a challenge in treating colorectal cancer (CRC) patients, contributory to the failure in chemotherapy. However, the mechanism of Oxaliplatin resistance has not been completely elucidated. In this study, we explored the key molecule involved in the Oxaliplatin resistance, which could be a candidate therapeutic target to attenuate chemo-resistance in CRC cells.Methods: Microarray screening, western blot and qPCR on clinic CRC samples were conducted to select the target gene ABCC10. The Oncomine Oncology Database and the Cancer Genome Atlas (TCGA) data were analyzed to figure out the correlation between the clinical manifestation and ABCC10. ABCC10 knock-down in CRC cells was conducted to identify its role in the Oxaliplatin resistance. Cell counting kit-8 (CCK-8) assay was conducted to identify the CRC cell viability and Oxaliplatin IC50. Flow cytometry was conducted to detect the cell apoptosis exposed to Oxaliplatin. The intracellular Oxaliplatin accumulation was measured by ultra-high performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS).Results: ABCC10 transporter was correlated with CRC relapse and metastasis, indicating a CRC-promoting effect of ABCC10. In ABCC10 knock-down CRC cells the Oxaliplatin sensitivity was significantly elevated due to an increase of intracellular Oxaliplatin accumulation resulted from the diminished drug efflux. We next explored a strategy to inhibit ABCC10 in CRC cells, paying a special interest in the endoplasmic reticulum stress (ERS) / unfolded protein response (UPR) that plays a dual role in tumor development. We found that the CRC cell viability was profoundly decreased and the pro-apoptotic factor CHOP and apoptosis were increased by the intense ERS/UPR instead of the inhibited and mild ERS/UPR. Significantly, the Oxaliplatin sensitivity of CRC cells was enhanced in response to the intense ERS, which was blocked by inhibiting IRE1α branch of UPR. Finally, we figured out that the intense ERS/UPR down-regulated ABCC10 via regulated IRE1-dependent decay (RIDD) activity. Conclusion: Oxaliplatin was a substrate of ABCC10. The intense ERS/IRE1α elicited anti-CRC effects through down-regulating ABCC10 so as to increase Oxaliplatin sensitivity, in addition to inducing CHOP. We suggested that introduction of intense ERS/UPR could be a promising strategy to restore chemo-sensitivity when used in combination with Oxaliplatin or other chemotherapeutic drugs pumped out by ABCC10.